According to Iovance Biotherapeutics 's latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 2615.92. At the end of 2023 the company had a P/S ratio of > 1000.
Year | P/S ratio | Change |
---|---|---|
2023 | > 1000 | |
2022 | N/A | |
2021 | N/A | |
2020 | N/A | |
2019 | N/A | |
2018 | N/A | |
2017 | N/A | |
2016 | N/A | |
2015 | N/A | |
2014 | N/A | |
2013 | N/A | |
2012 | N/A | |
2011 | N/A | |
2010 | N/A |
Company | P/S ratio | P/S ratio differencediff. | Country |
---|---|---|---|
Nymox Pharmaceutical NYMX | N/A | N/A | Bahamas |
NRC Health
NRC | 4.58 | -99.82% | ๐บ๐ธ USA |